Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
Key Highlights
- ➤INTerpath-001: intismeran plus KEYTRUDA improved recurrence-free survival versus KEYTRUDA alone
- ➤INTerpath-001: intismeran plus KEYTRUDA improved distant metastasis-free survival versus KEYTRUDA alone
- ➤TroFuse-005: sac-TMT improved overall and progression-free survival in advanced endometrial cancer
- ➤KEYNOTE-C93: first-line KEYTRUDA monotherapy data support use in certain dMMR endometrial cancer patients
- ➤Merck will present first Phase 3 results from three pivotal oncology trials at ESMO 2026
Expert Statements
Marjorie Green, Senior vice president and head of oncology global clinical development, Merck Research Laboratories
“New data at ESMO, including three Presidential Symposia from three pivotal trials, reflect the strength and depth of Merck’s industry-leading oncology portfolio and pipeline”
Marjorie Green, Senior vice president and head of oncology global clinical development, Merck Research Laboratories
“We are proud to share Phase 3 data for the first time from intismeran and sac-TMT, alongside new research from our oncology portfolio, reflecting our commitment to advancing research across a range of cancer types.”
Merck Showcases First-Time Pivotal Phase 3 Results From Oncology Pipeline and Continued Innovative Potential of Existing Portfolio at ESMO 2026
INTerpath-001 data to be presented in Presidential Symposium, featuring the first Phase 3 results for investigational intismeran autogene plus KEYTRUDA(®) (pembrolizumab), demonstrating improvements in recurrence-free survival and distant metastasis-free survival versus KEYTRUDA alone in patients with completely resected stage IIB-IV melanoma in the adjuvant setting
Get started
Create a free account to read the full story.